Suzhou Suncadia Biopharmaceuticals Co., Ltd.

This is a first-in-human study to test a new injectable drug called SHR-A1811(sc) in people with solid tumors. The main goals are to understand how the drug moves through the body, check its safety, and see if it shows any early signs of helping to control the cancer. The study w…

This study is testing whether a new three-drug combination works better than the current standard two-drug treatment for advanced lung cancer. It involves 460 adults with newly diagnosed, advanced non-small cell lung cancer who haven't had prior treatment. The trial directly comp…

This study is testing whether adding an experimental drug called SHR-A1912 to standard chemotherapy works better for people with aggressive lymphoma that has returned or stopped responding to previous treatments. Researchers will compare the new combination against the standard t…

This study is testing an investigational injection called SHR-2017 in adults with solid tumors that have spread to their bones. The main goals are to see if the treatment can help prevent serious bone complications, reduce bone pain, and lower markers of bone damage. Researchers …

This study is testing two different combinations of new drugs for people with stomach or gastroesophageal junction cancer who haven't had treatment yet. Researchers want to see if these drug combinations can shrink tumors effectively and are safe for patients. The trial will meas…

This early-stage study is testing a new drug called SHR-9839, given as an injection under the skin, in combination with other cancer therapies. It aims to find a safe and effective dose and see if it helps shrink tumors in adults with advanced solid cancers. The study will enroll…

This study is testing whether a new drug combination works better than current standard treatment for advanced stomach cancer that cannot be removed by surgery. The trial will involve 600 patients who haven't received previous treatment for their advanced cancer. Researchers will…

This study is testing a new drug called SHR-A1811, given with chemotherapy and/or immunotherapy, for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The first part checks the safety and best dose of the combinations. The second part measures how we…

This early-stage clinical trial is testing a new drug called SHR-1681 in patients with advanced solid tumors that have stopped responding to standard treatments. The study aims to find the safest and most effective dose, understand how the drug moves through the body, and see if …

This study is testing a new drug called SHR-1826, given alongside other cancer treatments, for people with advanced solid tumors. The main goals are to find a safe dose, see how well the body tolerates it, and measure if it helps shrink tumors. Researchers will enroll about 876 a…

This large, late-stage trial is testing whether adding a new drug called SHR-A2009 to the standard treatment (aumolertinib) works better for people with a specific type of advanced lung cancer. It will involve 576 adults who have not yet received treatment for their advanced canc…

This study compares a new two-drug combination (SHR-A2102 plus adebrelimab) against standard chemotherapy for people with advanced bladder cancer that hasn't been treated before. The trial aims to see if the new combination helps patients live longer without their cancer getting …

This study is testing whether a new drug called SHR-8068, when given alongside other cancer treatments, is safe and effective for people with colorectal cancer. It will involve about 200 adults and measure how well the combination shrinks tumors and controls the cancer's growth. …

This study is testing whether a new combination of two drugs (SHR-A1811 and SHR-1316) works better than the current standard treatment for advanced triple-negative breast cancer that has spread or returned. It's for women whose cancer tests positive for a marker called PD-L1. The…

This study is testing a new drug called SHR-3821 in people with advanced solid tumors to see if it's safe and how the body processes it. Researchers will enroll 162 adults with various advanced cancers to determine the right dose and look for early signs of effectiveness. This is…

This study is testing a new drug, SHR-A1811, combined with standard chemotherapy for ovarian cancer that has returned but still responds to platinum drugs. The main goals are to find the safest and most effective dose and to see how well the combination works to control the cance…

This is the first study in people to test a new drug called SHR-7782 for advanced cancer. The main goals are to find a safe dose and see if the drug shows any early signs of helping to control the cancer. It will enroll about 200 participants who have advanced cancer that has spr…

This study is testing a new combination of drugs (SHR-8068 and adebrelimab) for people with advanced kidney cancer that cannot be removed by surgery. The main goals are to find a safe dose and see how well the treatment shrinks tumors. It is for adults whose cancer has spread and…

This study compares a new three-drug combination (SHR-8068, adebrelimab, and chemotherapy) against the current standard treatment (durvalumab and chemotherapy) for advanced bile duct cancer. It aims to see if the new combination helps patients live longer while monitoring side ef…

This study is testing whether a new drug called SHR-4849, when combined with other cancer drugs, is safe and can help shrink tumors in people with advanced solid cancers. It will enroll about 120 adults with various cancers that have not responded to standard treatments. The main…